Two Sigma Investments LP Has $17.18 Million Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Two Sigma Investments LP reduced its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 35.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 397,549 shares of the company's stock after selling 221,365 shares during the period. Two Sigma Investments LP owned 0.42% of Scholar Rock worth $17,182,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC increased its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares during the last quarter. Amalgamated Bank increased its stake in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the last quarter. KBC Group NV bought a new stake in shares of Scholar Rock in the 4th quarter valued at about $131,000. Finally, NEOS Investment Management LLC bought a new stake in shares of Scholar Rock in the 4th quarter valued at about $209,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Scholar Rock

In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the transaction, the chief financial officer now owns 111,345 shares in the company, valued at $3,966,108.90. This represents a 56.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Katie Peng sold 1,006 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total transaction of $34,626.52. Following the transaction, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. The trade was a 3.21% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 154,798 shares of company stock worth $5,482,238. Insiders own 13.30% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Scholar Rock currently has a consensus rating of "Buy" and an average price target of $42.67.

Scholar Rock Stock Performance

Shares of SRRK stock traded up $0.02 on Wednesday, reaching $30.49. The stock had a trading volume of 99,726 shares, compared to its average volume of 1,266,094. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm's 50-day moving average is $30.63 and its two-hundred day moving average is $36.00. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -12.97 and a beta of 0.37. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter last year, the business posted ($0.59) EPS. On average, research analysts expect that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.